Oculis Holding 株価情報 (NASDAQ: OCS)

最新ニュース Oculis Holding (NASDAQ:OCS) 株価情報

Oculis Holding

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG

Oaktree Specialty Lending Corporation - Closed End Fund

Oaktree Specialty Lending Corp

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Delta Air Lines</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DAL, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 18 uncommon options trades for Delta Air Lines.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 61% bullish and 27%, bearish.</p>
<p>Out of all of the special options we uncovered, 7 are puts, for a total amount of $878,930, and 11 are calls, for a total amount of $691,867.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $72.5 for Delta Air Lines, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Delta Air Lines's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Delta Air Lines's significant trades, within a strike price range of $45.0 to $72.5, over the past month.</p>
<h3>Delta Air Lines Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306746_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$65.00</td>
<td>$320.0K</td>
<td>9.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$6.5</td>
<td>$6.3</td>
<td>$6.4</td>
<td>$55.00</td>
<td>$192.0K</td>
<td>39</td>
<td>300</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.77</td>
<td>$1.74</td>
<td>$1.87</td>
<td>$67.50</td>
<td>$169.2K</td>
<td>7.3K</td>
<td>14.7K</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$5.85</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$70.00</td>
<td>$166.5K</td>
<td>334</td>
<td>318</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.9</td>
<td>$2.87</td>
<td>$2.9</td>
<td>$65.00</td>
<td>$65.9K</td>
<td>23.1K</td>
<td>376</td>
</tr>
</tbody>
</table>
</p>
<h3>About Delta Air Lines</h3>
<p>Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.</p>
<p>Following our analysis of the options activities associated with Delta Air Lines, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Delta Air Lines</h3>
<ul>
<li>With a volume of 5,601,849, the price of DAL is down -2.23% at $64.72. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Delta Air Lines, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

A Closer Look at Delta Air Lines's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bullish approach towards Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAVA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 17 extraordinary options activities for Cava Group. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 52% leaning bullish and 41% bearish. Among these notable options, 2 are puts, totaling $1,122,484, and 15 are calls, amounting to $906,335.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $200.0 for Cava Group, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Cava Group options trades today is 503.15 with a total volume of 3,879.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cava Group's big money trades within a strike price range of $60.0 to $200.0 over the last 30 days.</p>
<h3>Cava Group Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306741_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$7.05</td>
<td>$6.8</td>
<td>$7.0</td>
<td>$125.00</td>
<td>$1.0M</td>
<td>269</td>
<td>2.5K</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.9</td>
<td>$10.8</td>
<td>$11.6</td>
<td>$200.00</td>
<td>$174.0K</td>
<td>1.5K</td>
<td>252</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$11.0</td>
<td>$10.55</td>
<td>$10.78</td>
<td>$200.00</td>
<td>$107.8K</td>
<td>1.5K</td>
<td>253</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$19.7</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$135.00</td>
<td>$97.5K</td>
<td>606</td>
<td>109</td>
</tr>
<tr>
<td>CAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$87.2</td>
<td>$85.3</td>
<td>$85.5</td>
<td>$60.00</td>
<td>$85.5K</td>
<td>49</td>
<td>12</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cava Group</h3>
<p>Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.</p>
<p>Having examined the options trading patterns of Cava Group, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Cava Group Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,578,028, with CAVA's price down by -5.41%, positioned at $133.01.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cava Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


CAVA

Cava Group Unusual Options Activity For February 11

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Biogen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIIB, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Biogen.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $634,880, and 5 are calls, for a total amount of $219,709.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $250.0 for Biogen during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Biogen's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale activity within a strike price range from $130.0 to $250.0 in the last 30 days. </p>
<h3>Biogen Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306736_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.8</td>
<td>$10.9</td>
<td>$140.00</td>
<td>$492.6K</td>
<td align="right">289</td>
<td align="right">458</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.4</td>
<td>$15.1</td>
<td>$15.4</td>
<td>$160.00</td>
<td>$93.9K</td>
<td align="right">85</td>
<td align="right">102</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.2</td>
<td>$10.7</td>
<td>$10.8</td>
<td>$140.00</td>
<td>$54.0K</td>
<td align="right">289</td>
<td align="right">508</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$139.00</td>
<td>$52.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$18.1</td>
<td>$17.3</td>
<td>$18.1</td>
<td>$130.00</td>
<td>$36.2K</td>
<td align="right">17</td>
<td align="right">20</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>In light of the recent options history for Biogen, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Biogen</h3>
<ul>
<li>Trading volume stands at 1,318,628, with BIIB's price down by -2.5%, positioned at $138.97.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Biogen</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Citigroup persists with their Neutral rating on Biogen, maintaining a target price of $160. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BIIB

Biogen's Options Frenzy: What You Need to Know

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) has outperformed the market over the past 5 years by 11.53% on an annualized basis producing an average annual return of 23.95%. Currently, Nucor has a market capitalization of $32.51 billion. </p>
<p><strong>Buying $100 In NUE:</strong> If an investor had bought $100 of NUE stock 5 years ago, it would be worth <strong>$294.08</strong> today based on a price of $138.46 for NUE at the time of writing.</p>
<h3>Nucor's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739306731_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


News

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<p><a href="https://www.newyorkfed.org/newsevents/speeches/2025/wil250211" title="https://www.newyorkfed.org/newsevents/speeches/2025/wil250211">https://www.newyorkfed.org/newsevents/speeches/2025/wil250211</a></p>


Macro Economic Events

Economics

Federal Reserve

Fed's Williams Says Labor Market In Good Balance, Not An Inflation Driver; Fed Has Made Significant Progress Lowering Inflation; Inflation Expectations Are Well Anchored; US Economy Is In A Good Place

Fed's Williams Says Monetary Policy Well Positioned To Achieve Fed Goals; Modestly Restrictive Policy Should Return Inflation To 2%; Economic Outlook Is Highly Uncertain Due In Part To Government Policy; Inflation To Hang Around 2.5% This Year, 2% In Coming Years; Us To Grow By Around 2% This Year And Next; Us Unemployment Rate Should Stay Between 4% To 4.25%

<p>Financial technology powerhouse <strong>Robinhood Markets Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) easily ranks among the top innovators, providing a convenient mechanism for the democratization of investing. </p>
<p>Naturally, Robinhood stock has absorbed significant interest, gaining about 350% over the past one-year period. Still, such astounding performances raise concerns about overvaluation — concerns that the smart money appears to be digesting.</p>
<p>In terms of the headline statistic, the biggest <a href="https://www.benzinga.com/insights/options/25/02/43628104/robinhood-markets-unusual-options-activity-for-february-11">unusual options trade</a> by far earlier today in terms of dollar value went to $50 call options featuring bullish sentiment. However, the total number of trades leaned bearishly, with 50% of investors opening trades with bearish expectations while 45% opened with bullish expectations.</p>
<p>Unfortunately, it's not such a cut-and-dry case. Late last week, the sentiment fissure was much more pronounced, with big-money traders splitting their funds 55% in the bearish direction and 34% in the bullish, with the remainder directed as neutral transactions.</p>
<p>Put another way, the most prudent approach may be to consider Robinhood stock as a volatility trade. However, there could be an argument for a directionally bullish wager considering the relative uptick in bullish transactions among the big-money traders.</p>
<p>Yes, on the surface, Robinhood&#8217;s stock seems wildly overvalued. For example, the equity currently trades at <a href="https://finance.yahoo.com/quote/hood/key-statistics">20.49-times trailing-12-month sales</a>. Around this point last year, this metric sat at only 9.62 times. However, analysts overall anticipate that Robinhood will generate $3.37 billion in revenue for fiscal 2025. Based on this projection, the forward sales multiple declines to a much more reasonable 14.2 times.</p>
<p>Moreover, investors must appreciate Robinhood's <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40752830/robinhood-shifted-from-meme-stock-to-market-contender-amid-new-products-and-global-">ambitious objectives</a>. As Barclays analyst Benjamin Budish noted last year, Robinhood's potential future growth enjoys several fresh catalysts: new products (like futures and credit cards), geographic expansion (particularly in the U.K.) and new channels, particularly in the cryptocurrency realm.</p>
<h2 class="wp-block-heading">Framing HOOD Stock as a ‘FOMO' Trade</h2>
<p>Perhaps the biggest takeaway regarding Robinhood stock from a trading perspective is that it responds aggressively to FOMO or the fear of missing out. In other words, this is a security that thrives on positive energy. However, speculators should also realize the opposite is also true: the stock price tends to tank on negative energy.</p>
<p>From a purely stochastic or temporal view, a position entered at the beginning of the week has around a 52.5% chance of rising by the end of it. The long odds continue to be above a coin toss in two and three-week intervals. However, by the end of the fourth week, the long odds dip slightly to 49.17%.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-1024x576.jpg" alt="" class="wp-image-777252" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11144027/HOOD-stock-probability-gambit.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption"><em>Image by author</em></figcaption></figure></p>
<p>On a dynamic basis (accounting for certain conditions), the probabilities fluctuate noticeably. For example, last week, the stock gained 15.2%. Historically, whenever Robinhood gained between 10% and 20% during a one-week period, the long odds for the subsequent week spiked to around 73%. By the end of the fourth subsequent week following this extreme-greed event, the long odds are still favorable at 60%.</p>
<p>Interestingly, investors do not show a tendency of buying the dips in the company&#8217;s stock. Following a weekly loss between 10% and 20%, the chances that Robinhood will rise in the subsequent week lands at only 35.3%. Over the course of four weeks, long odds are even worse at 29.4%.</p>
<p>That's not to say that these statistical tendencies guarantee a move in one direction or another because they absolutely do not. However, investors should realize that strength in Robinhood stock continues to bolster more strength. At the same time, severe corrections tend to scare off traders, adding to the high-stakes atmosphere.</p>
<h2 class="wp-block-heading">Plotting an Effective Options Strategy for Robinhood</h2>
<p>Arguably, the most sensible options-based approach for the company is to treat it as a volatility trade. One week after the aforementioned extreme-greed event (which coincides with the options chain expiring Feb. 14), the median return under the positive scenario is 3.07% while the median loss under the negative scenario is 4.93%. Based on last Friday's close as the anchor, that would target a high of $57.57 and a low of $53.11.</p>
<p>Complicating matters, though, is the wildly high <a href="https://optioncharts.io/options/HOOD/volatility-skew">implied volatility</a> (IV) of approximately 168%. Essentially, IV represents the market's anticipation of mobility in the target asset. Using reverse engineering which accounts for the time decay of options, market makers are anticipating a move of $8.27 in either direction; therefore, roughly $62.48 at the high or $45.94 at the low.</p>
<p>One approach may involve splitting the difference between the two data sets, thus targeting $60 at the high and around $50 at the low. For this trade, one could consider the 50P &#x7C; 52P &#x7C;&#x7C; 58C &#x7C; 60C long iron condor for the options chain expiring this Friday.</p>
<p>The above transaction combines the 50/52 bear put spread and the 58/60 bull call spread, with the maximum payout triggered if Robinhood stock rises to $60 or falls to $50. At time of writing, a trader risks $140 for the chance to earn a maximum of $60.</p>
<p>Of course, the long iron condor features a less-attractive reward profile because the trader is essentially paying two premiums. On the other hand, for traders who believe in the bullish statistical tendency, the framework becomes quite alluring.</p>
<p>As an example, long speculators may consider the 57/60 bull call spread for the options chain expiring March 7. This transaction requires a net debit of $99 for the chance to earn a maximum reward of $201. That's a payout of 203% compared to the long iron condor's 43% payout.</p>
<p><strong>Now Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take&#8217; And Cherish Gaza</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Earnings

Movers

HOOD

Options Corner: Smart Money Is In Fierce Tug-Of-War Ahead Of Robinhood Earnings

<p><strong>Reddit Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) could highlight how AI data licensing deals are helping the company's improving financials and profitability when the company reports fourth-quarter financial results after <a href="https://www.benzinga.com/earnings">market close Wednesday.</a></p>
<p><br /><strong>Earnings Estimates</strong>: Analysts expect Reddit to report fourth-quarter revenue of $404.63 million according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a></p>
<p>The company has beaten analyst estimates for revenue in three straight quarters since going public. Here are the quarterly revenue totals for the fiscal year:</p>
<ul>
<li>First Quarter: $242.96 million</li>
<li>Second Quarter: $281.18 million</li>
<li>Third Quarter: $348.35 million</li>
</ul>
<p>Analysts expect the company to report earnings per share of 25 cents for the fourth quarter. The company has beaten analyst estimates for three straight quarters, included the third quarter which had a profit of 16 cents per share.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/general/social-media/25/01/43291797/exclusive-will-social-media-users-leave-over-politics-new-poll-shows-this-platform-hurt-most">EXCLUSIVE: Will Social Media Users Leave Over Politics? New Poll Shows This Platform Hurt Most</a></strong></p>
<p><strong>Key Items to Watch</strong>: Reddit's earnings report comes as AI continues to be a trending topic and monetization opportunity for many companies and sectors.</p>
<p>Reddit was early to the trend of media companies being <a href="https://www.benzinga.com/news/24/03/37898537/reddit-is-selling-you-to-artificial-intelligence-firms-should-you-care">paid to license out</a> their data to the likes of Google and OpenAI for AI models. These deals have helped boost the financials for Reddit and will be among the most watched items in the quarterly results.</p>
<p>Analysts and investors expect to see strong revenue growth and improving profitability in the quarter.</p>
<p>Analysts have been bullish on Reddit in recent weeks. Here are the <a href="https://www.benzinga.com/quote/RDDT/analyst-ratings">recent analyst ratings</a> and price targets on Reddit:</p>
<ul>
<li>Raymond James: Maintained Strong Buy rating, raised price target from $200 to $250</li>
<li>Seaport Global: Initiated with Neutral rating, no price target</li>
<li>JMP Securities: Reiterated market Outperform, $190 price target</li>
<li>Roth MKM: Downgraded from Buy to Neutral, raised price target from $116 to $195</li>
</ul>
<p>Since going public in March 2024, Reddit has been one of the top-performing IPOs in recent history. Shares priced at $34 and the stock closed at $50.44 in its market debut. Shares are up significantly since that time.</p>
<p>Expectations are likely high for Reddit, which could mean a strong quarter and strong guidance is needed to send shares higher.</p>
<p><br /><strong>RDDT Price Action</strong>: Reddit stock is down 4.6% to $214.80 on Tuesday versus a 52-week trading range of $37.35 to $230.41. Reddit stock is up 29.5% year-to-date in 2024 and up over 325% in the last year.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/03/37995982/3-reddit-executives-sold-too-early-and-missed-out-on-19m-in-additional-gains-from-ipo"><strong>3 Reddit Executives Sold Too Early And Missed Out On $19M In Additional Gains From IPO</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Sports Betting

RDDT

Reddit Q4 Earnings Preview: Can Recently Public Company Beat Estimates Four Straight Quarters?

<p><strong>Intel Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading higher on Tuesday, driven by comments from U.S. <strong>Vice President JD Vance </strong>about protecting American artificial intelligence and <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43635364/us-stocks-dip-as-powell-stays-cautious-intel-climbs-tesla-sinks-to-11-week-low">semiconductor technologies</a>.</p>
<p><strong>What To Know:</strong> <a href="https://www.cnbc.com/2025/02/11/intel-rises-after-vp-vance-promises-to-safeguard-american-ai-and-chips.html">According to CNBC</a>, the stock reacted to Vance's remarks at the Paris AI summit, where he pledged to block foreign adversaries from stealing and misusing AI for military and intelligence purposes.</p>
<p>Vance stated that authoritarian regimes have exploited AI for surveillance, propaganda, and military advancements and that the U.S. would take aggressive action to prevent such activities. While he did not directly mention China's DeepSeek AI, he emphasized the need for international cooperation to limit adversarial access to AI technology.</p>
<p>Intel has struggled to regain its position in the semiconductor industry after losing significant market share to competitors like Nvidia and Broadcom. The stock fell 60% last year as the company lagged in AI chip development. In its most recent earnings report, Intel posted a third consecutive quarter of declining revenue and issued a weak forecast. The company is also undergoing leadership changes following the departure of CEO <strong>Pat Gelsinger.</strong></p>
<p>Despite its challenges, Intel has secured billions in government subsidies to build semiconductor manufacturing facilities in the U.S. as part of an effort to strengthen domestic production. The company is currently led by interim co-CEOs <strong>David Zinsner and Michelle Johnston Holthaus.</strong></p>
<p><strong>INTC Price Action: </strong>Intel corporation shares were up 6.42% at $21.04 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1">Benzinga pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-1024x530.png" alt="" class="wp-image-777290" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11150906/Screenshot-2025-02-11-at-15.08.44.png 1532w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/25/02/43637482/trump-gaza-cherish-it-white-house-meeting-with-jordans-king-abdullah">Trump Says We Will &#8216;Take Gaza&#8217; And &#8216;Cherish It&#8217; In White House Meeting With Jordan&#8217;s King Abdullah</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


INTC

Intel Shares Are Up Today: What's Going On?

<p>Boeing&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Starliner program has turned into a costly and embarrassing failure. The aerospace giant has spent more than $2 billion on the troubled spacecraft, including $523 million in charges just in 2024, according to a filing with the U.S. Securities and Exchange Commission.&nbsp;</p>
<p>This financial catastrophe is the result of numerous delays, technical malfunctions, and growing testing and certification expenses. NASA and Boeing originally agreed to a <a href="https://www.benzinga.com/startups/24/07/40026075/boeing-wins-space-mission-contracts-owing-to-its-armies-of-lobbyists-says-spacex-ceo-elon-musk-amid">$4.2 billion contract</a> for the development of Starliner, but due to ongoing failures and significant overruns, the program is now among the most costly commercial space missions in history.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks"><strong>See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</strong></a></strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>
<h2 class="wp-block-heading">Boeing's $2 Billion Problem</h2>
<p>The Starliner program has been plagued with delays, technical failures, and massive cost overruns. The spacecraft was supposed to be NASA's second option for sending astronauts to and from the International Space Station, alongside <strong>SpaceX</strong>'s Crew Dragon. But since its first crewed test flight in June, the Starliner has faced thruster malfunctions, helium leaks, and other serious issues.</p>
<p>These problems meant <strong>Butch Wilmore</strong> and <strong>Suni Williams</strong> couldn't return home on Starliner as planned. NASA had to send the spacecraft back to Earth uncrewed and later announced that the astronauts would return on a SpaceX Crew Dragon instead. Boeing had already taken multiple financial hits on the project, including a $489 million charge in 2019 and now another $523 million in 2024, further driving up the total losses.</p>
<p><strong>Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-nancy-pelosi"><strong>Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000</strong></a></strong></p>
<h2 class="wp-block-heading">Musk and Trump Stir Up Controversy</h2>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">The <a href="https://twitter.com/POTUS?ref_src=twsrc%5Etfw">@POTUS</a> has asked <a href="https://twitter.com/SpaceX?ref_src=twsrc%5Etfw">@SpaceX</a> to bring home the 2 astronauts stranded on the <a href="https://twitter.com/Space_Station?ref_src=twsrc%5Etfw">@Space_Station</a> as soon as possible. We will do so.<br /><br />Terrible that the Biden administration left them there so long.</p>
<p>&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1884365928038563880?ref_src=twsrc%5Etfw">January 28, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Despite NASA making this decision months ago, <strong>Elon Musk</strong> and <strong>Donald Trump</strong> made headlines by claiming that the astronauts were &#8220;stranded.&#8221; Musk posted on X that SpaceX would rescue the astronauts after <a href="https://www.benzinga.com/general/space/25/01/43310082/trump-calls-on-musk-to-rescue-stranded-astronauts-but-nasa-picked-spacex-last-year">Trump asked him to step in</a>. Trump went even further on his social media, saying the Biden administration had &#8220;abandoned&#8221; Wilmore and Williams in space.</p>
<p>This claim caught many by surprise because NASA had already arranged for SpaceX to bring them back as part of its Crew-9 mission, which launched in September with two empty seats specifically for their return. Despite NASA&#8217;s repeated assurances that the astronauts were never stranded and always had a way home, Musk&#8217;s remarks caused confusion.</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it"><strong><em>Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</em></strong></a></em></strong></p>
<h2 class="wp-block-heading">Politics and Space Contracts</h2>
<p>Trump&#8217;s remarks and Musk&#8217;s involvement may have detrimental effects on Boeing. Trump's administration seems keen on shifting more <a href="https://www.benzinga.com/news/24/10/41414968/spacex-wins-major-us-space-force-contract-worth-734m-for-national-security-missions">NASA contracts</a> toward SpaceX. He has even <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42323934/shift4-payments-stock-drops-after-ceo-jared-isaacmans-nasa-nomination-whats-going-on">nominated <strong>Jared Isaacman</strong></a>, a SpaceX ally and <a href="https://www.benzinga.com/general/space/24/09/40842633/public-company-ceo-goes-to-space-is-there-risk-for-shareholders-when-billionaires-pursue-space-drea">private astronaut</a>, to lead NASA. This move could signal a big shift away from Boeing and toward Musk's company for future space missions.</p>
<p>Boeing, already struggling with commercial jet issues and financial losses, now faces an uncertain future in the space sector. Some analysts speculate that Boeing may exit the Starliner program altogether, especially as the ISS is set to be retired within the next five years. There were even reports that Boeing was considering selling its entire space division last year.&nbsp;</p>
<p>For now, Wilmore and Williams remain on the ISS, where they've been for over seven months—far longer than their planned one-week mission. They have continued working on ISS maintenance and spacewalks while awaiting their return.</p>
<p>NASA has confirmed that <a href="https://www.benzinga.com/24/12/42571318/return-of-astronauts-sunita-williams-and-butch-wilmore-from-iss-further-delayed-now-expected-no-earlier-than-late-march">Crew-9 will bring them home</a> in March or April, once Crew-10 arrives to replace them.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>If there was a new fund backed by Jeff Bezos offering a</strong><strong> <a href="https://www.benzinga.com/money/arrived-private-credit-fund"><strong>7-9% target yield with monthly dividends would you invest in it</strong></a>?</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>


Boeing Has Spent $2 Billion On The Starliner Debacle As Musk's SpaceX Set To Rescue The Stranded Astronauts

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Praxis Precision Medicine</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PRAX, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Praxis Precision Medicine.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $160,892, and 6 are calls, for a total amount of $345,368.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $100.0 for Praxis Precision Medicine over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Praxis Precision Medicine's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Praxis Precision Medicine's significant trades, within a strike price range of $75.0 to $100.0, over the past month.</p>
<h3>Praxis Precision Medicine Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305828_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.6</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$90.00</td>
<td>$132.7K</td>
<td>72</td>
<td align="right">761</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$20.7</td>
<td>$19.9</td>
<td>$19.9</td>
<td>$75.00</td>
<td>$71.7K</td>
<td>1.6K</td>
<td align="right">37</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$90.00</td>
<td>$65.4K</td>
<td>72</td>
<td align="right">248</td>
</tr>
<tr>
<td>PRAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$7.6</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$90.00</td>
<td>$64.6K</td>
<td>72</td>
<td align="right">767</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$75.00</td>
<td>$51.1K</td>
<td>32</td>
<td align="right">250</td>
</tr>
</tbody>
</table>
</p>
<h3>About Praxis Precision Medicine</h3>
<p>Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.</p>
<h3>Praxis Precision Medicine's Current Market Status</h3>
<ul>
<li>With a volume of 291,328, the price of PRAX is down -0.09% at $84.77. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What The Experts Say On Praxis Precision Medicine</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $145.33333333333334.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Praxis Precision Medicine with a target price of $175.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $150.<br />
&#x2A; In a cautious move, an analyst from Deutsche Bank downgraded its rating to Buy, setting a price target of $111. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Praxis Precision Medicine options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


PRAX

What the Options Market Tells Us About Praxis Precision Medicine

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Take-Two Interactive</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TTWO, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for <strong>Take-Two Interactive</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 22% bullish and 55%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $28,520, and 8, calls, for a total amount of $389,093.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $250.0 for Take-Two Interactive over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Take-Two Interactive's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Take-Two Interactive's significant trades, within a strike price range of $150.0 to $250.0, over the past month.</p>
<h3>Take-Two Interactive Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305823_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.4</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$250.00</td>
<td>$88.2K</td>
<td>1.1K</td>
<td align="right">99</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$8.85</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$250.00</td>
<td>$80.0K</td>
<td>1.1K</td>
<td align="right">265</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$9.1</td>
<td>$8.6</td>
<td>$8.85</td>
<td>$250.00</td>
<td>$63.7K</td>
<td>1.1K</td>
<td align="right">173</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$70.5</td>
<td>$69.7</td>
<td>$70.5</td>
<td>$150.00</td>
<td>$35.2K</td>
<td>321</td>
<td align="right">5</td>
</tr>
<tr>
<td>TTWO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$33.9</td>
<td>$33.5</td>
<td>$33.5</td>
<td>$240.00</td>
<td>$33.5K</td>
<td>24</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Take-Two Interactive</h3>
<p>Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three quarters of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.</p>
<p>Following our analysis of the options activities associated with Take-Two Interactive, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Take-Two Interactive</h3>
<ul>
<li>Trading volume stands at 924,561, with TTWO's price down by -1.54%, positioned at $209.23.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 93 days.</li>
</ul>
<h3>Expert Opinions on Take-Two Interactive</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $213.6.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Stifel persists with their Buy rating on Take-Two Interactive, maintaining a target price of $223.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Take-Two Interactive, targeting a price of $230.<br />
&#x2A; An analyst from MoffettNathanson has decided to maintain their Neutral rating on Take-Two Interactive, which currently sits at a price target of $170.<br />
&#x2A; An analyst from Raymond James downgraded its action to Outperform with a price target of $220.<br />
&#x2A; Reflecting concerns, an analyst from Benchmark lowers its rating to Buy with a new price target of $225.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Take-Two Interactive, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


TTWO

Take-Two Interactive's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bearish approach towards IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in IREN usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 47 extraordinary options activities for IREN. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 53% bearish. Among these notable options, 20 are puts, totaling $6,390,984, and 27 are calls, amounting to $1,378,685.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $6.0 to $25.0 for IREN over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in IREN's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to IREN's substantial trades, within a strike price spectrum from $6.0 to $25.0 over the preceding 30 days.</p>
<h3>IREN 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305818_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$1.2M</td>
<td>11.3K</td>
<td>3.2K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$825.2K</td>
<td>11.3K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$4.5</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$15.00</td>
<td>$594.4K</td>
<td>50</td>
<td>1.3K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$15.00</td>
<td>$578.2K</td>
<td>50</td>
<td>5.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$20.00</td>
<td>$501.2K</td>
<td>11.3K</td>
<td>560</td>
</tr>
</tbody>
</table>
</p>
<h3>About IREN</h3>
<p>IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.</p>
<p>In light of the recent options history for IREN, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of IREN</h3>
<ul>
<li>With a volume of 6,738,850, the price of IREN is down -3.73% at $12.38. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IREN options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


IREN

Decoding IREN's Options Activity: What's the Big Picture?

<p>Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has outperformed the market over the past 10 years by 14.01% on an annualized basis producing an average annual return of 25.16%. Currently, Microsoft has a market capitalization of $3.06 trillion. </p>
<p><strong>Buying $1000 In MSFT:</strong> If an investor had bought $1000 of MSFT stock 10 years ago, it would be worth <strong>$9,432.08</strong> today based on a price of $411.62 for MSFT at the time of writing.</p>
<h3>Microsoft's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739305817_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MSFT

Here's How Much You Would Have Made Owning Microsoft Stock In The Last 10 Years

<p>The <strong>Travelers Companies, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) announced Tuesday that it expects $1.7 billion in pretax catastrophe losses from the California wildfires that swept through the state in January. After taxes, the estimated <a href="https://www.benzinga.com/quote/TRV/news">loss amounts to $1.3 billion</a>.</p>
<p>The insurer said the estimate includes losses from its personal and commercial segments, as well as assessments from the California FAIR Plan, the state's insurer of last resort. Recoveries from reinsurance have been factored into the estimate.</p>
<p>Analysts have projected that total industry losses from the wildfires could reach $30 billion. Other insurers are also reporting significant impacts. Last week, Allstate said it expects about $1.1 billion in pretax catastrophe losses from the fires, net of reinsurance.</p>
<p>Travelers&#8217; announcement follows a challenging period for insurers operating in California, where wildfire risk has led several companies to scale back coverage or raise premiums. The FAIR Plan, which provides limited fire insurance for homeowners unable to get coverage elsewhere, can require insurers to help fund claims.</p>
<p>Travelers said it is actively working to process claims and assist affected policyholders. CEO <strong>Alan Schnitzer</strong> acknowledged the scale of the disaster, noting the company&#8217;s commitment to supporting customers and communities impacted by the fires.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/technicals/25/02/43636110/stock-of-the-day-does-classic-head-shoulders-pattern-mean-snap-goes-lower">Stock Of The Day: Does Classic Head &amp; Shoulders Pattern Mean Snap Goes Lower?</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Travelers Expects $1.7 Billion In Catastrophe Losses From California Wildfires

<p>Cryptocurrency markets are trading lower on Tuesday, with Bitcoin tapping the $95,000 level.  </p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$95,189.97</td>
<td>-2.3%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,600.05</td>
<td>-2.8%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$196.61</td>
<td>-2.8%</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.40</td>
<td>-1%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2519</td>
<td>-0.7%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001559&nbsp;&nbsp;</td>
<td>-1.5%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 52.2% and daily active addresses growing by 20.2%. Transactions greater than $100,000 are up from 7,194 to 9,866 in a single day. Exchanges netflows are down by 137.2%.</li>
<li>Coinglass data reports 121,611 traders were liquidated in the past 24 hours for $217.83 million.</li>
<li>Martinez <a href="https://x.com/ali_charts/status/1889378618901668006">noted</a> that whales recently realized almost $800 million in BTC profits.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43618900/apple-vs-ibit-bitcoin-etf-one-is-warren-buffetts-berkshire-hathaways-biggest-holding-the-other-gives-exposure-to-a-crypto-he-vehemently-dislikes-which-has-generated-better-yearly-returns">Apple Vs IBIT Bitcoin ETF: One Is Warren Buffett&#8217;s Berkshire Hathaway&#8217;s Biggest Holding, The Other Gives Exposure To A Crypto He Vehemently Dislikes, Which Has Generated Better Yearly Returns?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43632945/bitcoin-solana-rise-in-january-but-ethereum-lagging-jpmorgan">Bitcoin, Solana Rise In January, But Ethereum Lagging: JPMorgan</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43622299/poland-rejects-bitcoin-reserves-as-czech-republic-and-us-explore-crypto-holdings">Poland Rejects Bitcoin Reserves As Czech Republic And US Explore Crypto Holdings</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43614251/hacker-pleads-guilty-to-secs-fake-bitcoin-etf-post-on-x-that-triggered-financial-wipeout-worth-millions">Hacker Pleads Guilty To SEC&#8217;s Fake Bitcoin ETF Post On X That Triggered Financial Wipeout Worth Millions</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43624201/ranking-the-xrp-dogecoin-solana-litecoin-etf-approval-chances-one-altcoin-has-a-90-chance-bloomberg-analyst-says">Ranking The XRP, Dogecoin, Solana, Litecoin ETF Approval Chances: One Altcoin Has A 90% Chance, Bloomberg Analyst Says</a></li>
</ul>
<p><strong>Top Losers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Onyxcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">XCN</a>)</td>
<td>&nbsp;$0.02132</td>
<td>-10.8%</td>
</tr>
<tr>
<td><strong>Ethena</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ENA</a>)</td>
<td>&nbsp;$0.4441</td>
<td>-8.3%</td>
</tr>
<tr>
<td><strong>Aptos</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>)</td>
<td>&nbsp;$5.87</td>
<td>-5.4%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>With Bitcoin prices falling, crypto trader Altcoin Sherpa anticipates one final move down before recovery, expecting altcoins to retest previous lows while maintaining a relative bottom.</p>
<p> He remains flat on active positions but plans to bid the next dip, particularly in AI coins like ARC.</p>
<p> He also highlights the 100-day EMA approaching and expects the wick to be filled.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">1 final move down for <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> before the recovery imo. Alts prob test near those lows they made before but I still think &#x2A;relative&#x2A; bottom is in. Flat on active positions but looking to bid this next move down for AI coins like arc. <br /><br />100d EMA coming up + wick usually gets filled <a href="https://t.co/jimsBVCZwi">pic.twitter.com/jimsBVCZwi</a></p>
<p>&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1889396689590435954?ref_src=twsrc%5Etfw">February 11, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Meanwhile, CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1889400972482617668">notes</a> that Bitcoin is holding its higher timeframe (HTF) support zone, expecting continued consolidation as long as it holds. </p>
<p>He anticipates a dip below $94,100, a reclaim, and a push to local supply above recent highs, but remains cautious, saying, &#8220;Let&#8217;s see how things develop.&#8221;</p>
<p>Crypto analyst Ali Martinez reaffirmed his earlier outlook, warning that Bitcoin, XRP, Solana and Cardano could see a brief pullback. The TD Sequential indicator is flashing a sell signal on hourly charts.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">told y&#39;all! <a href="https://t.co/YaJ1gUNpWQ">https://t.co/YaJ1gUNpWQ</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1889311239630663829?ref_src=twsrc%5Etfw">February 11, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43627642/the-bitcoin-4-year-cycle-is-dead-analyst-says-adapt-or-die">The Bitcoin 4-Year Cycle Is Dead, Analyst Says: &#8216;Adapt Or Die&#8217;</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$APT

$BTC

$DOGE

$ENA

$ETH

$SHIB

$SOL

$XCN

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Slide Lower: 'Final Move Down Before The Recovery,' Trader Says

<p><strong>Goldman Sachs</strong> downgraded <strong>Regenxbio Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>), citing gene therapy&#8217;s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39234044/goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upsid" rel="noreferrer noopener">lasting effects at lower costs</a>.</p>
<p>Analyst Paul Choi writes that <strong>AbbVie Inc</strong> partnered ABBV-RGX-314 faces growing competition, with its invasive delivery method making it less favorable than rival treatments.</p>
<p>Data from the ATMOSPHERE&nbsp;and ASCENT&nbsp;pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with Wet Age-Related Macular Degeneration (wet AMD) are expected in 2026.</p>
<p>AbbVie and REGENXBIO will plan a Phase 3 clinical program for ABBV-RGX-314 in&nbsp;Diabetic Retinopathy with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42944040/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program" rel="noreferrer noopener">suprachoroidal delivery</a>.</p>
<p>The analyst downgraded Regenxbio to Neutral from Buy and reduced the price forecast <a href="https://www.benzinga.com/quote/RGNX/analyst-ratings" target="_blank" rel="noreferrer noopener">to $14 from $38 prior</a>.</p>
<p>Goldman Sachs writes that additional competing treatments are progressing in the clinic, including <strong>EyePoint Pharmaceuticals</strong> <strong>Inc.&#8217;s </strong>Duravyu (vorolanib intravitreal insert), for which the company recently presented <a href="https://www.benzinga.com/pressreleases/25/02/g43490361/eyepoint-announces-positive-six-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for" target="_blank" rel="noreferrer noopener">topline 6-month results</a>.</p>
<p>The analyst views the appeal of gene therapies in retinal disease overall as decreasing, thus reducing the assumed share of patients who are likely to opt for these treatments. This, in turn, leads to meaningfully lowering projected peak sales for ABBV-RGX-314.</p>
<p>As more people adopt the treatment, the analyst expects prices to keep declining despite changes in the ASP+ system. Ultimately, this could set a lower price benchmark for ABBV-RGX-314 as it nears commercialization.</p>
<p>Separately, the analyst highlights the increasing use of <strong>Regeneron</strong> <strong>Pharmaceutical Inc&#8217;s</strong> 2 mg Eylea biosimilars, which have taken share from the branded version despite the availability of Eylea HD.</p>
<p>Goldman analyst Choi finds the current data on RGX-202 (gene therapy for Duchenne muscular dystrophy) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42033036/regenxbio-initiates-pivotal-phase-of-affinity-duchenne-trial-of-rgx-202-gene-therapy-and-reports-p" rel="noreferrer noopener">promising but limited</a>. Choi also sees a growing need for better treatments, citing interest in <strong>Sarepta Theraputics Inc&#8217;s</strong> Elevidys and strong enrollment in <strong>Edgewise Therapeutics&#8217; </strong>FOX study for post-gene therapy care.</p>
<p>Last month, Regenxbio and Nippon Shinyaku announced a strategic partnership to develop and commercialize RGX-121 for Mucopolysaccharidosis II, also known as Hunter syndrome, and RGX-111 for Mucopolysaccharidosis I, also <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42967827/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership-to-develop-and-commercialize-rgx-121-" rel="noreferrer noopener">known as Hurler syndrome</a>.</p>
<p>Regenxbio will receive&nbsp;$110 million&nbsp;and up to an additional&nbsp;$700 million&nbsp;if certain milestones are achieved, consisting of&nbsp;$40 million&nbsp;in potential development and regulatory milestones and&nbsp;$660 million&nbsp;in potential sales milestones.</p>
<p><strong>Price Action:</strong> RGNX stock is down 7.29% at $7.315 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43629604/kelloggs-q4-earnings-beat-expectations-despite-challenging-market-conditions" target="_blank" rel="noreferrer noopener">WK Kellogg Q4: EPS Beat, Sales Miss Amid Challenging Market Conditions</a></strong></li>
</ul>
<p><em>Image via Shutterstock.</em></p>


Analyst Color

Biotech

Equities

Downgrades

Health Care

Price Target

Analyst Ratings

General

RGNX

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Pfizer</strong>.</p>
<p>Looking at options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) we detected 15 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $345,963 and 12, calls, for a total amount of $1,524,951.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $30.0 for Pfizer over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $20.0 to $30.0 in the last 30 days. </p>
<h3>Pfizer Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739304945_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.98</td>
<td>$0.93</td>
<td>$0.98</td>
<td>$25.00</td>
<td>$245.0K</td>
<td>5.8K</td>
<td>2.5K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.98</td>
<td>$0.98</td>
<td>$0.98</td>
<td>$25.00</td>
<td>$232.7K</td>
<td>5.8K</td>
<td>2.4K</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.6</td>
<td>$1.53</td>
<td>$1.53</td>
<td>$25.00</td>
<td>$229.5K</td>
<td>4.4K</td>
<td>13</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.0</td>
<td>$0.85</td>
<td>$1.0</td>
<td>$25.00</td>
<td>$217.7K</td>
<td>5.8K</td>
<td>9.6K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$23.00</td>
<td>$175.5K</td>
<td>680</td>
<td>500</td>
</tr>
</tbody>
</table>
</p>
<h3>About Pfizer</h3>
<p>Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.</p>
<p>In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Pfizer</h3>
<ul>
<li>Currently trading with a volume of 22,984,668, the PFE's price is down by -1.26%, now at $25.55. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $31.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Guggenheim downgraded its action to Buy with a price target of $33.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Pfizer with a target price of $29. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Pfizer's Options Frenzy: What You Need to Know

<p>Benzinga's options scanner has just identified more than 14 option transactions on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>), with a cumulative value of $566,975. Concurrently, our algorithms picked up 8 puts, worth a total of 272,605.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $130.0 and $180.0 for Celestica, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Celestica's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celestica's whale trades within a strike price range from $130.0 to $180.0 in the last 30 days. </p>
<h3>Celestica Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739304940_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.6</td>
<td>$8.3</td>
<td>$8.6</td>
<td>$130.00</td>
<td>$199.5K</td>
<td>1.3K</td>
<td align="right">338</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$180.00</td>
<td>$114.4K</td>
<td>361</td>
<td align="right">181</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$58.0</td>
<td>$55.5</td>
<td>$55.5</td>
<td>$165.00</td>
<td>$44.4K</td>
<td>4</td>
<td align="right">8</td>
</tr>
<tr>
<td>CLS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$39.5</td>
<td>$39.0</td>
<td>$39.0</td>
<td>$150.00</td>
<td>$42.9K</td>
<td>11</td>
<td align="right">12</td>
</tr>
<tr>
<td>CLS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$7.1</td>
<td>$6.3</td>
<td>$6.6</td>
<td>$180.00</td>
<td>$41.5K</td>
<td>361</td>
<td align="right">334</td>
</tr>
</tbody>
</table>
</p>
<h3>About Celestica</h3>
<p>Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.</p>
<h3>Celestica's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,090,984, the price of CLS is down by -2.23%, reaching $127.32.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Celestica</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $136.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Celestica with a target price of $139.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Celestica with a target price of $140.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Celestica, which currently sits at a price target of $160.<br />
&#x2A; Maintaining their stance, an analyst from TD Securities continues to hold a Buy rating for Celestica, targeting a price of $107. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Celestica, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


A Closer Look at Celestica's Options Market Dynamics

<p>Financial giants have made a conspicuous bullish move on Dollar Tree. Our analysis of options history for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 46% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $875,042, and 4 were calls, valued at $271,340.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $67.0 to $78.0 for Dollar Tree over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Dollar Tree options trades today is 2097.0 with a total volume of 39,395.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Dollar Tree's big money trades within a strike price range of $67.0 to $78.0 over the last 30 days.</p>
<h3>Dollar Tree 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739304936_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$4.0</td>
<td>$3.45</td>
<td>$3.5</td>
<td>$71.00</td>
<td>$175.0K</td>
<td align="right">1</td>
<td>7.1K</td>
</tr>
<tr>
<td>DLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$4.0</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$71.00</td>
<td>$174.6K</td>
<td align="right">1</td>
<td>6.6K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$5.45</td>
<td>$2.28</td>
<td>$3.5</td>
<td>$76.00</td>
<td>$122.5K</td>
<td align="right">0</td>
<td>350</td>
</tr>
<tr>
<td>DLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.95</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$71.00</td>
<td>$103.5K</td>
<td align="right">1</td>
<td>8.1K</td>
</tr>
<tr>
<td>DLTR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$3.95</td>
<td>$3.35</td>
<td>$3.45</td>
<td>$71.00</td>
<td>$103.5K</td>
<td align="right">1</td>
<td>7.8K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dollar Tree</h3>
<p>Dollar Tree operates discount stores across the United States and Canada, with over 8,800 shops under its namesake banner and 7,700 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. Dollar Tree sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two thirds of Family Dollar's stores are in urban and suburban markets, with the remaining one third located in rural areas.</p>
<p>In light of the recent options history for Dollar Tree, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Dollar Tree</h3>
<ul>
<li>Currently trading with a volume of 831,027, the DLTR's price is down by -1.99%, now at $72.39. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 29 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dollar Tree with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


DLTR

A Closer Look at Dollar Tree's Options Market Dynamics

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Oculis Holding (OCS – Research Report). The c...

Bank of America Securities Sticks to Its Buy Rating for Oculis Holding (OCS)

Oculis ($OCS), a global biopharmaceutical company dedicated to eye care treatments, recently reported disappointing results for the most recent qua...

Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors

Bank of America Securities Sticks to Their Buy Rating for Oculis Holding (OCS)

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding (OCS – Research Report) and keeping the price target at $30.00. Yi C...

Oculis Holding's OCS-05 Receives Buy Rating Amid Promising Clinical Data and Regulatory Advancements

Oculis Holding ( ($OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in...

Oculis Holding's OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis

BofA raised the firm's price target on Oculis (OCS) to $31 from $23 and keeps a Buy rating on the shares. The company reported Phase 2 results from...

Oculis price target raised to $31 from $23 at BofA

Oculis Holding (OCS) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy. Annabel Samimy has given her Buy rating d...

Promising Clinical Results and Market Potential Drive Buy Rating for Oculis Holding

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

President Trump temporarily halts leasing and permitting for wind energy projects

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

ACCD

AGEN

ALTR

ALXO

ARLUF

CANF

CELH

COST

DNNGY

DXST

ENGIY

FBGL

FTNT

GLXZ

GMVHF

INKT

INTU

ISRG

ITCI

JSPR

KURA

MMYT

MNST

MSTR

MVRK

NFLX

OCSAW

QBTS

RGTI

RWEOY

SIEGY

SLXN

SMEGF

SMPL

SSNLF

TOPP

TSX:VG

TWLO

VWDRY

Press Releases

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Oculis to Present at Upcoming September Investor Conferences

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Management

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis to Present at the Stifel 2024 Healthcare Conference

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Comments

Oculis Holding

ニュース

最新ニュース Oculis Holding (NASDAQ:OCS) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル